Viking Therapeutics down 4% despite quarterly bottom line beat

seekingalpha04-25

Shares of Viking Therapeutics (NASDAQ:VKTX) are down ~4% in after-hours trading Wednesday, even though the company's Q1 2024 financial results beat on the bottom line. Viking did not report any ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430492058?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186975279/image_186975279.jpg","is_english":true,"pubTime":"2024-04-25 06:25","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2430492058","market":"sg","top_or_hot":-1,"title":"Viking Therapeutics down 4% despite quarterly bottom line beat","media":"seekingalpha","content":"<div>\n<p>Shares of Viking Therapeutics (NASDAQ:VKTX) are down ~4% in after-hours trading Wednesday, even though the company's Q1 2024 financial results beat on the bottom line. Viking did not report any ...</p>\n\n<a href=\"https://seekingalpha.com/news/4093765-viking-therapeutics-down-4-despite-quarterly-bottom-line-beat\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics down 4% despite quarterly bottom line beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics down 4% despite quarterly bottom line beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 06:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4093765-viking-therapeutics-down-4-despite-quarterly-bottom-line-beat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Viking Therapeutics (NASDAQ:VKTX) are down ~4% in after-hours trading Wednesday, even though the company's Q1 2024 financial results beat on the bottom line. Viking did not report any ...</p>\n\n<a href=\"https://seekingalpha.com/news/4093765-viking-therapeutics-down-4-despite-quarterly-bottom-line-beat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4093765-viking-therapeutics-down-4-despite-quarterly-bottom-line-beat","article_id":"2430492058","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186975279/image_186975279.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430492058","pubTimestamp":1713997510,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Viking Therapeutics  are down ~4% in after-hours trading Wednesday, even though the company's Q1 2024 financial results beat on the bottom line. Viking did not report any revenue. The company's net loss in the quarter widened to ~$27.4M from ~$19.5M in the year-ago period. Basic and diluted net loss per share was -$0.26 compared to -$0.25 in Q1 2023.  In the quarter, Viking grew its total assets to ~$967.5M on March 31. That figure stood at ~$368.5M on Dec. 31, 2023. The company added that it is on track to release data from the secondary and exploratory objectives of the VOYAGE study, which is a phase 2 study of VK2809 for non-alcoholic steatohepatitis , later this quarter.   More on Viking Therapeutics  Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight?Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics gains on early data for oral weight loss therapy Jefferies star","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"Viking Therapeutics下跌4%，尽管季度利润超过预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1},"content_text":"Shares of Viking Therapeutics (NASDAQ:VKTX) are down ~4% in after-hours trading Wednesday, even though the company's Q1 2024 financial results beat on the bottom line. Viking did not report any revenue. The company's net loss in the quarter widened to ~$27.4M from ~$19.5M in the year-ago period. Basic and diluted net loss per share was -$0.26 compared to -$0.25 in Q1 2023.  In the quarter, Viking grew its total assets to ~$967.5M on March 31. That figure stood at ~$368.5M on Dec. 31, 2023. The company added that it is on track to release data from the secondary and exploratory objectives of the VOYAGE study, which is a phase 2 study of VK2809 for non-alcoholic steatohepatitis (NASH), later this quarter.   More on Viking Therapeutics  Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight? Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics gains on early data for oral weight loss therapy Jefferies starts Viking Therapeutics at buy, cites \"scarcity value\"","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430492058"}